Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay

Kavita Panwar; Anna Godi; Clementina E. Cocuzza; Nick Andrews; Jo Southern; Paul Turner; Elizabeth Miller; Simon Beddows

doi:10.1016/j.mex.2022.101776

Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay

Kavita Panwar, Anna Godi, Clementina E. Cocuzza, Nick Andrews, Jo Southern, Paul Turner, Elizabeth Miller, Simon Beddows^*

^*Corresponding author for this work

UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability of individual and population level vaccine immunity. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses against multiple antigens at the same time, usually at reduced per sample cost and a more efficient use of available samples. Consequently, multiplex serology is an essential component of a wide range of public health programmes. Human papillomavirus (HPV) serology is limited to a small number of academic, public health and vaccine manufacturer laboratories globally. Such platforms include indirect binding to the major (L1) capsid protein virus-like particles (VLP), monoclonal antibody competition against L1 VLP and indirect binding to L1 and L2 (minor capsid protein) VLP on multiplex (Luminex®, Meso Scale Discovery®) and standard (ELISA) platforms. The methodology described here utilizes a common multi-analyte platform and L1L2-based VLP expressed in house, which allows the simultaneous detection and quantification of antibody responses against nine vaccine-relevant HPV genotypes.

Original language	English
Article number	101776
Journal	MethodsX
Volume	9
DOIs	https://doi.org/10.1016/j.mex.2022.101776
Publication status	Published - Jan 2022

Bibliographical note

Funding Information:
This work was supported by the UK Health Security Agency.

Funding Information:
We are indebted to Prof. John T. Schiller and Dr. Chris Buck (National Cancer Institute, Bethesda, MD. U.S.A.) for the psheLL L1L2 vector used to make the L1L2 antigens used for this method. We thank Drs Ligia Pinto and Troy Kemp of Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. MD. U.S.A. as the source of nonavalent vaccine serum used to make the standards and IQC. We thank Busayo Elegunde, Ayesha Febis and Farida Abdulkadir for their excellent technical assistance with the execution of this work. This work was supported by the UK Health Security Agency.

Publisher Copyright:
© 2022

Keywords

Antibody
Binding
Human papillomavirus
Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mex.2022.101776

Cite this

@article{b44b12f996934e6881fbdacc1e2b5305,

title = "Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay",

abstract = "A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability of individual and population level vaccine immunity. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses against multiple antigens at the same time, usually at reduced per sample cost and a more efficient use of available samples. Consequently, multiplex serology is an essential component of a wide range of public health programmes. Human papillomavirus (HPV) serology is limited to a small number of academic, public health and vaccine manufacturer laboratories globally. Such platforms include indirect binding to the major (L1) capsid protein virus-like particles (VLP), monoclonal antibody competition against L1 VLP and indirect binding to L1 and L2 (minor capsid protein) VLP on multiplex (Luminex{\textregistered}, Meso Scale Discovery{\textregistered}) and standard (ELISA) platforms. The methodology described here utilizes a common multi-analyte platform and L1L2-based VLP expressed in house, which allows the simultaneous detection and quantification of antibody responses against nine vaccine-relevant HPV genotypes.",

keywords = "Antibody, Binding, Human papillomavirus, Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay, Vaccine",

author = "Kavita Panwar and Anna Godi and Cocuzza, {Clementina E.} and Nick Andrews and Jo Southern and Paul Turner and Elizabeth Miller and Simon Beddows",

note = "Funding Information: This work was supported by the UK Health Security Agency. Funding Information: We are indebted to Prof. John T. Schiller and Dr. Chris Buck (National Cancer Institute, Bethesda, MD. U.S.A.) for the psheLL L1L2 vector used to make the L1L2 antigens used for this method. We thank Drs Ligia Pinto and Troy Kemp of Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. MD. U.S.A. as the source of nonavalent vaccine serum used to make the standards and IQC. We thank Busayo Elegunde, Ayesha Febis and Farida Abdulkadir for their excellent technical assistance with the execution of this work. This work was supported by the UK Health Security Agency. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jan,

doi = "10.1016/j.mex.2022.101776",

language = "English",

volume = "9",

journal = "MethodsX",

issn = "2215-0161",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay

AU - Panwar, Kavita

AU - Godi, Anna

AU - Cocuzza, Clementina E.

AU - Andrews, Nick

AU - Southern, Jo

AU - Turner, Paul

AU - Miller, Elizabeth

AU - Beddows, Simon

N1 - Funding Information: This work was supported by the UK Health Security Agency. Funding Information: We are indebted to Prof. John T. Schiller and Dr. Chris Buck (National Cancer Institute, Bethesda, MD. U.S.A.) for the psheLL L1L2 vector used to make the L1L2 antigens used for this method. We thank Drs Ligia Pinto and Troy Kemp of Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. MD. U.S.A. as the source of nonavalent vaccine serum used to make the standards and IQC. We thank Busayo Elegunde, Ayesha Febis and Farida Abdulkadir for their excellent technical assistance with the execution of this work. This work was supported by the UK Health Security Agency. Publisher Copyright: © 2022

PY - 2022/1

Y1 - 2022/1

N2 - A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability of individual and population level vaccine immunity. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses against multiple antigens at the same time, usually at reduced per sample cost and a more efficient use of available samples. Consequently, multiplex serology is an essential component of a wide range of public health programmes. Human papillomavirus (HPV) serology is limited to a small number of academic, public health and vaccine manufacturer laboratories globally. Such platforms include indirect binding to the major (L1) capsid protein virus-like particles (VLP), monoclonal antibody competition against L1 VLP and indirect binding to L1 and L2 (minor capsid protein) VLP on multiplex (Luminex®, Meso Scale Discovery®) and standard (ELISA) platforms. The methodology described here utilizes a common multi-analyte platform and L1L2-based VLP expressed in house, which allows the simultaneous detection and quantification of antibody responses against nine vaccine-relevant HPV genotypes.

AB - A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability of individual and population level vaccine immunity. Multiplex (or multi-analyte) platforms are increasingly being used to evaluate immune responses against multiple antigens at the same time, usually at reduced per sample cost and a more efficient use of available samples. Consequently, multiplex serology is an essential component of a wide range of public health programmes. Human papillomavirus (HPV) serology is limited to a small number of academic, public health and vaccine manufacturer laboratories globally. Such platforms include indirect binding to the major (L1) capsid protein virus-like particles (VLP), monoclonal antibody competition against L1 VLP and indirect binding to L1 and L2 (minor capsid protein) VLP on multiplex (Luminex®, Meso Scale Discovery®) and standard (ELISA) platforms. The methodology described here utilizes a common multi-analyte platform and L1L2-based VLP expressed in house, which allows the simultaneous detection and quantification of antibody responses against nine vaccine-relevant HPV genotypes.

KW - Antibody

KW - Binding

KW - Human papillomavirus

KW - Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85133222359&partnerID=8YFLogxK

U2 - 10.1016/j.mex.2022.101776

DO - 10.1016/j.mex.2022.101776

M3 - Article

AN - SCOPUS:85133222359

SN - 2215-0161

VL - 9

JO - MethodsX

JF - MethodsX

M1 - 101776

ER -

Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this